Endometriosis 1990. Current treatment approaches.

Area of Science:

• Gynecological disease research
• Reproductive endocrinology
• Pharmacological treatment of endometriosis

Background:

• Endometriosis affects 1-5% of reproductive-age women, presenting with pelvic pain, infertility, or endometriomas.
• Surgical intervention is primary for endometriomas, with potential need for long-term hormone therapy post-surgery.
• Hormonal therapy effectively manages endometriosis-related pelvic pain in most patients, but not infertility.

Purpose of the Study:

• To review current hormonal treatment options for endometriosis.
• To compare the efficacy and side effect profiles of different hormonal regimens.
• To identify the need for improved endometriosis treatment strategies.

Main Methods:

• Review of randomized controlled trials comparing hormonal therapies for endometriosis.
• Analysis of efficacy data for danazol, GnRH agonists, progestins, and combined estrogen-progestin therapies.
• Evaluation of reported side effects associated with each treatment modality.

Main Results:

• Danazol and gonadotropin-releasing hormone (GnRH) agonists demonstrate comparable efficacy in treating endometriosis.
• Danazol causes androgenic side effects (e.g., weight gain, hirsutism, acne).
• GnRH agonists induce hypoestrogenic side effects (e.g., hot flashes, osteoporosis, vaginal dryness).

Conclusions:

• Current hormonal treatments for endometriosis, including danazol and GnRH agonists, offer similar effectiveness but distinct side effect profiles.
• The optimal hormonal regimen for endometriosis treatment has yet to be determined.
• Further research is needed to develop ideal drug therapies with improved tolerability and efficacy.